Skip to main content Back to Top
Advertisement

2/23/2017

Sodium Acetate Injection

Products Affected - Description

    • Sodium acetate injection, American Regent, 2 mEq/mL, 20 mL vial, 25 count, NDC 00517-2096-25
    • Sodium acetate injection, American Regent, 4 mEq/mL, 50 mL vial, 25 count, NDC 00517-5023-25

Reason for the Shortage

    • American Regent has sodium acetate injection on long-term back order due to manufacturing delays. It is unclear if and when they will return to market.
    • Fresenius Kabi has sodium acetate injection available.
    • Pfizer has sodium acetate injection available.

Available Products

    • Sodium acetate injection, Fresenius Kabi, 4 mEq/mL, 100 mL vial, 25 count, NDC 63323-0032-61
    • Sodium acetate injection, Pfizer, 2 mEq/mL, 100 mL vial, 25 count, NDC 00409-3299-06
    • Sodium acetate injection, Pfizer, 2 mEq/mL, 20 mL vial, 25 count, NDC 00409-7299-73
    • Sodium acetate injection, Pfizer, 2 mEq/mL, 50 mL vial, 25 count, NDC 00409-3299-05

Estimated Resupply Dates

    • American Regent has sodium acetate 2 mEq/mL 20 mL vials and 4 mEq/mL 50 mL vials on long-term back order and the company cannot estimate a release date.
    • All other marketed presentations are available.

Updated

Updated February 23, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. Created December 30, 2015 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.